DeepHealth boosts ultrasound AI by integrating See-Mode team
See-Mode's commercially available AI-powered ultrasound detection, characterisation, and reporting solutions for thyroid and breast will be added to DeepHealth's suite of services. These technologies automatically detect and characterise thyroid nodules and breast lesions during ultrasound imaging, aiming to improve diagnostic accuracy and streamline clinical workflows through the generation of standardised reports.
The integration is set against the backdrop of rising global rates of thyroid cancer, which is among the fastest-growing cancer diagnoses worldwide. Alongside breast cancer, it remains a prevalent pathology, particularly impacting women.
Real-world deployment of See-Mode's FDA-cleared thyroid ultrasound AI at selected RadNet imaging centres has already shown operational benefits, with workflow efficiency improvements and enhancements to diagnostic accuracy. The company reported that the inclusion of See-Mode's automated detection and reporting has resulted in up to a 30 per cent reduction in scan time in the centres where it has been piloted.
Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant."
Dr. Berger further noted, "Early deployment of See-Mode's FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode's automated detection and reporting. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centers. Furthermore, there is already a reimbursement code that makes a portion of our approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement. We aim to expand these efficiencies to breast screening and other clinical areas in our more than two million annual ultrasound studies. These opportunities will also be sold and marketed by DeepHealth to third parties as we further commercialize the offerings."
See-Mode's AI technologies are currently cleared for commercial distribution in the United States, Canada, Australia, New Zealand, and Singapore. The acquisition supports DeepHealth's stated objective to strengthen its portfolio of AI-driven population health solutions and to address clinical and operational challenges in high-volume care settings.
Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: "Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth's combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound."
Echoing these remarks, Kees Wesdorp, President and Chief Executive Officer of RadNet's Digital Health division, said: "We are excited to integrate See-Mode's technology in thyroid and breast ultrasound into DeepHealth's comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team's expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth."
According to the information provided, DeepHealth currently operates more than 900 ultrasound units, conducting over two million ultrasound examinations each year. The company expects that the integration of See-Mode's technology will allow it to manage greater demand, improve workflow efficiencies, and address current appointment slot limitations.
Industry sources cited in the release note that in the United States alone, approximately 20 million ultrasound exams are performed each year for thyroid and breast combined. RadNet and DeepHealth aim to capitalise on these volumes by promoting their expanded suite of AI-driven solutions to both internal and third-party customers.
See-Mode's team and technology base in Singapore and Australia will join the DeepHealth operations, contributing their expertise to ongoing and future development of AI-driven ultrasound solutions. This collaboration is expected to facilitate the development of new applications in high-volume diagnostic imaging and to support improved access and outcomes across RadNet's network of imaging centres.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NZ Herald
3 days ago
- NZ Herald
FDA pushes to restrict synthetic opioid derived from kratom leaf
'We think it's night and day in terms of the public health risk,' Makary said of 7-OH products. The agency is recommending to the Drug Enforcement Administration that 7-OH be classified as Schedule I, a tier designated to have no medical value and high risk of abuse. That tier still includes marijuana, which federal officials under the Biden Administration sought to move to a less restrictive category. That issue remains undecided. The law enforcement agency will review the 7-OH recommendation 'expeditiously', DEA Deputy Assistant Administrator Thomas Prevoznik said. Federal health officials rolled out the campaign to stamp out 7-OH with the nation still in the throes of a drug crisis fuelled by illicit fentanyl, methamphetamine, and other synthetic compounds easily manufactured in clandestine labs. Overdose deaths have dropped dramatically during the past year but still topped a staggering 80,000 in 2024. Health and Human Services Secretary Robert F. Kennedy jnr, who himself battled a heroin addiction decades ago, said that public health agencies have been 'asleep at the wheel' on previous crises of addiction in the US. The FDA's report presented scientific studies on 7-OH and advisories to consumers and doctors warning them of 'eye-catching' products sold as gummies, candies, and even ice-cream cones meant to appeal to young people. This month, the FDA said it had sent warning letters to seven companies regarding allegations that they illegally marketed 7-OH products as dietary supplements or unapproved drugs that touted relief from pain or anxiety. The scrutiny of 7-OH products adds another twist to the saga of kratom in the US. Amid the nation's drug crisis, kratom has become increasingly popular as users seek alternatives for pain or relief from opioid withdrawal symptoms. Smoke shops, service stations, convenience stores and online retailers across the US sell to devoted users who champion the health benefits of all-natural kratom products on social media. Speaking at the news conference today, kratom advocate Melody Woolf drew a distinction between the powdered kratom leaf she takes to ease her chronic pain and 7-OH products. Woolf said: '7-OH is not what helped me get out of bed and get the quality of life I enjoy'. Kratom acts as a mild stimulant when taken in small doses. Experts say that in higher doses, kratom's compounds can induce euphoria similar to opioids, though with less potency than many legal painkillers. One of kratom's many natural compounds is converted into the metabolite 7-OH, or 7-hydroxymitragynine, which produces an opioid-like effect in the brain. Though kratom contains trace amounts of the compound naturally, companies use semisynthetic 7-OH extracts to make an entirely new and potent product, said Christopher McCurdy, professor of medicinal chemistry at the University of Florida College of Pharmacy. 'This is essentially putting legal morphine at the gas station,' McCurdy said. Retailers have been slapped with wrongful-death lawsuits from families of people who died with kratom compounds in their blood, usually in conjunction with illicit drugs. In 2016, the Drug Enforcement Administration announced plans to classify kratom compounds as controlled substances but shelved the idea after a fierce backlash. More than a dozen states have passed laws regulating kratom, according to the American Kratom Association, a trade group representing the industry. The association casts companies selling 'enhanced' 7-OH products as bad actors that offer 'chemically manipulated' products – usually concentrated shots and tablets. The products distort the public's understanding of kratom and provide ammunition to critics who seek to ban plant products, said Mac Haddow, a spokesman and lobbyist for the association. 'We do not believe these products should be available over the counter,' Haddow said in an interview yesterday. An opposing trade association, the Holistic Alternative Recovery Trust, said the criticism is part of an 'intra-industry turf war' between companies losing market share and those making better products. 'Consumers find it more effective and safer,' Jeff Smith, the group's national policy director, said of such 7-OH products. Smith said the group supports measures such as warning labels, age restrictions and testing by third-party independent labs. But he criticised the FDA's proposals, saying officials presented no science to support the alleged dangers of 7-OH. He predicted a ban would push users to return to more dangerous substances and destroy responsible businesses. 'The public needs to speak up to prevent dramatic regulatory over-reach,' Smith said.
Techday NZ
21-07-2025
- Techday NZ
Check Point earns CREST accreditation for penetration testing
Check Point Software Technologies has confirmed that its Infinity Global Services Penetration Testing team has been awarded CREST accreditation for penetration testing services. The CREST accreditation recognises companies that adhere to strict standards relating to technical capability, ethical conduct and quality assurance within the field of penetration testing. This status indicates that Check Point's services meet international benchmarks for diligence and credibility, providing customers with an additional layer of assurance in an increasingly regulated cyber environment. Check Point executives emphasise that the accreditation reflects both the company's methodology and ethical standards in offensive security. Eitan Lugassi, Vice President of Infinity Global Services at Check Point Software Technologies, stated, "This accreditation reflects our dedication to delivering the highest level of security assurance to our customers. CREST certification is a globally recognised symbol of quality and integrity. It tells our customers that they can trust our penetration testing to deliver meaningful insights, follow best practices and support compliance with international standards." Through CREST-accredited penetration testing, Check Point will now provide services designed to identify, assess and remedy vulnerabilities using proven methods and peer-reviewed processes. The accreditation process itself evaluates both organisational practices and technical proficiency to maintain high ethical and operational standards. CREST, as a not-for-profit accreditation body, provides certifications only after comprehensive audits of technical strategy, ethical frameworks and quality management systems within participating organisations. For Check Point, achieving this recognition demonstrates the strength of its internal controls and the expertise of its testing teams. Infinity Global Services, a cyber security division within Check Point, oversees a broad collection of cyber security offerings. The team consists of over 450 professionals who provide support and incident response services around the clock. By deploying real-time threat intelligence, Infinity Global Services enables clients to detect and mitigate cyber threats as they arise, and to respond rapidly to cyber incidents that affect business continuity. According to Check Point, its CREST-accredited penetration testing encompasses several core offerings. These include expert-led testing that simulates real-world cyber attack scenarios, which are structured around CREST-approved methodologies to ensure review consistency and technical precision. Actionable reporting forms another component, with each assessment delivering prioritised recommendations that clients can integrate into their security posture. The company also highlights the integration of testing programmes with up-to-date threat intelligence across sectors and regions. This is intended to foster ongoing improvement by adapting to evolving attack tactics and supporting large-scale IT environments. Check Point's service track record includes experience with millions of IT assets across various industries worldwide. As regulatory pressures increase, especially around compliance and transparency, CREST certification offers organisations assurance that their chosen security partners meet stringent industry standards for ethical behaviour and technical depth. Check Point claims its accredited service provides enhanced transparency and professionalism, giving clients greater confidence in the assessments conducted on their infrastructure. Key components of Check Point's accredited testing include the use of CREST-aligned methodologies, simulation of real-world attacks, recommendations prioritised for customer action, and integration of findings with threat intelligence for continual adaptation to the evolving threat landscape. Check Point reiterates that the CREST accreditation underlines its commitment to providing reliable, rigorous, and globally validated penetration testing services for organisational cyber defence, recognising its capability in managing complex environments and its dedication to high-assurance security practices.
Otago Daily Times
18-06-2025
- Otago Daily Times
'For jet lag and insomnia': Psilocybin to be prescribed, melatonin to be sold over-the-counter
The government has signalled melatonin will become available over the counter, and psilocybin - magic mushrooms - will be available for patients with treatment-resistant depression. Psilocybin will still be an "unapproved medicine" but will be able to be granted under the authority of one specific highly experienced psychiatrist. Melatonin is a natural hormone that helps induce sleep, and is used to treat insomnia and jet lag, but has been classified as a prescription-only medicine in New Zealand. It will be available in pharmacies as pills up to 5mg in packs with up to 10 days' supply, or pills up to 3mg. "Modified release doses" - pills, capsules, gels and medical devices which allow the drug to be administered over a specific period - could also be available with dosages of up to 2mg. No specific date has been set for when the changes will take effect. Associate Health Minister David Seymour announced the decisions on Wednesday afternoon, noting they were made by MedSafe rather than politicians. "Certainly I've discussed with some of them ... some of them were very enthusiastic about the melatonin but ultimately they respect that it's a technical decision for MedSafe." He said melatonin would become available once manufacturers began to export it to New Zealand. "You'll be able to go to any pharmacy and buy melatonin for jet lag and insomnia just as soon as it's available over the counter in New Zealand. Part of the purpose of my announcement today is to call on the melatonin manufacturers of the world to apply to bring their products into our country," Seymour said. "When we did this with pseudoephedrine, it was a matter of months before products were on the shelves and I hope we can beat that record. "Kiwis shouldn't be left counting sheep or desperate for options when other countries are already using these medicines. The government is committed to putting patients first ... this is a commonsense decision that will make melatonin more accessible in New Zealand than in many other countries." The change for psilocybin was a huge win for people with depression who had tried everything else, Seymour said. "If a doctor believes psilocybin can help, they should have the tools to try. The psychiatrist involved has previously prescribed psilocybin in clinical trials and will operate under strict reporting and record-keeping requirements." He said it would initially only be available from one specific psychiatrist, but he hoped more would apply. "Psilocybin is a medicine that can treat untreatable depression. It was first researched in the 1950s and '60s and more recently there's been extensive research and approvals by the FDA in the United States to be able to use these types of medicines. "Fair to say it's been driven by people in the profession - there's a lot of people very passionate about this because untreatable depression's an awful thing and there are clinicians who say there's stuff happening in the rest of the world and we need to be part of it." He had never taken either of them, nor pseudoephedrine. "No. No I have not inhaled melatonin but maybe I will. I've had some recent issues with jet lag of my own so hopefully in the future I'll be able to," Seymour said. "I used to go mushroom hunting with my dad as a very small kid, but I don't think we found any." The melatonin changes were confirmed in regulations gazetted by Medsafe group manager Chris James. The psilocybin changes were not yet gazetted, but it will mark the first time psilocybin will be legally available in New Zealand outside of clinical trials.
